Here's the hot news from Danaher $DHR (+0,78Â %) (NYSE: DHR) Q3 2026 earnings release, fresh off the US stock market open:
🚀 Top-line on track: Solid growth in line with expectations
Danaher posted solid results in the third quarter of 2026, continuing the recovery trend in the life sciences and bioprocessing markets:
Revenue: ~$6.56 billion → approx. +8.4% YoY.
Expectations met exactly: Analysts’ estimates of ~$6.56 billion were met exactly.
Core Revenue Growth: +2.0% to +3.0% YoY (adjusted for currency effects and acquisitions).
Core Revenue ex-Respiratory: ~+5.0% YoY. Excluding the decline in Cepheid’s COVID-19 and flu testing business, the operating momentum looks noticeably stronger.
The bottom line: The life sciences giant confirms a gradual return to normalcy following the post-COVID inventory adjustment phase in the pharmaceutical industry.
đź’° Bottom Line: Efficiency machine delivers
Danaher leverages its in-house optimization system (DBS = Danaher Business System) and maintains high margins:
Non-GAAP / Adjusted EPS: $1.92 → slightly beats analyst estimates and hits the upper end of the expected range spot on (previous year: $1.89).
Adjusted Operating Profit Margin: Stable and strong at around 26.5%.
Cash Flow Strength: Continues to reliably generate over $1.2 to $1.5 billion in free cash flow per quarter.
Not a spectacular record-breaker like NVIDIA, but a brutally predictable, high-quality margin.
🧪 Biotechnology & Life Sciences: The bioprocessing bottom has been reached
The most important operational point in the report:
Biotechnology & Bioprocessing: Order intake in the bioprocessing division continues to rise. Pharmaceutical customers’ inventories have largely been depleted, which is why consumables are once again being ordered steadily.
Diagnostics (including Masimo): The Masimo segment (acquired this summer for ~$9.8 billion) is being rapidly integrated and is already contributing to positive growth.
New Leadership & AI Partnership: New CEO Julie Sawyer Montgomery is reporting for the first time. In addition, shortly before the earnings release, Danaher announced an official NVIDIA partnership for AI-powered lab workflow automation.
⚠️ But Jack is hitting the brakes: What’s the problem?
The numbers are solid and clean, but Danaher continues to struggle with familiar headwinds:
1. No organic “super-explosive” growth catalyst: With a P/E ratio of ~26–27x forward EPS, the market won’t tolerate a snail’s pace. While core growth of 2–3% across the entire group is in line with guidance, it’s not exactly blowing value-growth investors away.
2. China slowdown & academic budgets: The Chinese market, as well as government and academic research budgets, remain sluggish and are currently preventing a return to double-digit organic growth rates.
⚡ Jack’s Conclusion
Danaher delivered exactly what was announced. No nasty surprises, but also no excessive beat.
~$6.56 billion in revenue (+8.4% reported).
Adj. EPS of $1.92.
Core growth (excluding Respiratory) at +5.0%.
Fundamentals: An absolute quality powerhouse in the medtech/life sciences sector with an enormously wide moat (Moat 4/4).
Operational momentum: Solid bottoming-out process; bioprocessing is picking up noticeably again.
Valuation/Expectations: Fairly priced—sustained double-digit EPS growth will be needed again in 2027 for the next real breakout in the stock price.
Jack’s Rating for the Earnings Report: 🟡/🟢 “A clean, expected win without any surprises.”